Analytical Data
-
Gene name
HLA-A*02:01&B2M&MART-1(ELAGIGILTV) Tetramer
- Application
-
Alternative Names
MART1; LB39-AA; SK29-AA; Melan-A; MLANA
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&ELAGIGILTV
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/MART-1 (ELAGIGILTV) tetramer is a crucial tool in immunological research, particularly in understanding T cell responses against melanoma. MART-1, a melanoma-associated antigen, is a critical target for T cell-mediated immunity in patients with melanoma. HLA-A*02:01, the most prevalent class I human leukocyte antigen, presents the MART-1 peptide (ELAGIGILTV) to CD8+ T cells, facilitating the recognition and elimination of melanoma cells. The generation of tetramers composed of HLA-A*02:01, beta-2-microglobulin (B2M), and the MART-1 peptide allows for the precise identification and characterization of MART-1 specific T cells in peripheral blood and tumor microenvironments. This has significant implications for the development of targeted immunotherapies. By quantifying the frequency and functional capacity of these T cells, researchers can better understand the immune landscape of melanoma and the efficacy of therapeutic interventions, such as vaccines or checkpoint inhibitors. The use of tetramer technology has revolutionized the assessment of T cell responses, providing insights into tumor immunity, T cell exhaustion, and the overall role of the immune system in cancer progression and treatment outcomes.
